FDA Advisory Committee Recommends Against Approving Tarceva For First-Line Maintenance Use In Advanced Non-Small Cell Lung Cancer

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy…

Go to Source

People who read this also read

• FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg For Maintenance Of Remission Of Hepatic Encephalopathy
  Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE). "We are very pleas...
• FDA Advisory Committee Recommends Approval Of InterMune’s Esbriet(R) (pirfenidone) For Idiopathic Pulmonary Fibrosis
  InterMune, Inc. (Nasdaq: ITMN) announced that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung fu...
• Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
  Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocar...
• FDA Advisory Committee Recommends Approval Of Belatacept
  Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney t...
• FDA Advisory Committee To Review Lux Biosciences’ Uveitis Candidate Luveniq™
  Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis involving the interme...